-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- CUSTOMER EXPERIENCE MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DOCUMENT MANAGEMENT
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards
Young Shon, CIOThe Lund, Sweden-based CRO offers end-to-end services that include clinical development planning, study and onsite coordination, patient recruitment, clinical data management, biostatistics, pharmacovigilance, safety, regulatory affairs and medical writing. With expertise in clinical development and focus on performing phase 2 to phase 4 trials, TFS offers scientific and medical advice on planning a trial. The company assists in protocol design, which is a crucial part in trial planning and strategizing for meeting regulations and submission to regulatory agencies. Young further elaborates how TFS stands apart from its larger compeers by adhering to a consultative approach. While larger CROs advise on improving the protocol design, TFS questions whether the client aims to improve the protocol design. The client’s affirmative answer is met with knowledge sharing and application of deep know-how in trial management.
“With our suite of CRO services, we trump our smaller peers and cost-effectiveness allows us to race past our larger competitors. We have combined our customer intimacy and flexibility, with our full line of service, capabilities, and people,” states Young. Currently, TFS is focused on serving in therapeutic areas such as Oncology/Hematology, Dermatology, Ophthalmology, Cardiovascular, Immunology/Inflammation, CNS and Endocrinology with its network of investigators and clinical sites.
TFS moves further to transform areas allied with clinical research, applies its holistic approach for transforming risk-based monitoring, a key to a successful clinical trial, to enhance the quality and safety of a study. The firm applies cutting-edge technology underpinned by machine learning and analytics to receive warnings triggered by the risks associated with the clinical study. By automating this crucial process that involves data verification and the human element, the company significantly eliminates the high cost.
TFS holds an edge over its larger competitors with its ability to connect disparate systems and facilitate data transition. As the company is not banking on a particular technology, it is agile in addressing the varying business needs of its clients with the right technology. The leadership of the company looks forward to building technology solutions and services and create success stories akin to the specialty pharma company. TFS has already set its mark in Europe and been expanding its network in the U.S. to triumph in the transatlantic market.
TFS has also automated the repetitive and rule-based tasks associated with clinical research. As its solution can perform the repetitive tasks and mimic the human efforts, the outcome is faster clinical research. The firm fetches data and leverages it to add efficacy in the existing processes using the third party solutions.
Secret sauce to our success is our ability to address changing business needs and build long-lasting bonds woven by value creation and flexibility
TFS holds an edge over its larger competitors with its ability to connect disparate systems and facilitate data transition. As the company is not banking on a particular technology, it is agile in addressing the varying business needs of its clients with the right technology. The leadership of the company looks forward to building technology solutions and services and create success stories akin to the specialty pharma company. TFS has already set its mark in Europe and been expanding its network in the U.S. to triumph in the transatlantic market.
TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation
Wednesday, March 20, 2024
LUND – TFS HealthScience (TFS), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia. This strategic move marks a significant milestone in TFS's commitment to providing comprehensive clinical research services and supporting partners with a broader reach to patients, fostering innovative solutions and global collaboration.
The APAC region presents a promising landscape for clinical research, with a diverse patient population encompassing various ethnicities, demographics, and medical conditions. According to the Clinical Leader, the APAC CRO market is expected to grow to US$12 billion by 2025. TFS recognizes the potential to contribute significantly to advancing medical knowledge and improving patient outcomes in this vibrant and growing market.
Dr. Bassem Saleh, Chief Executive Officer at TFS, expressed his enthusiasm for the expansion, stating, "As we extend our footprint into the APAC region, Australia emerges as a strategic focal point for establishing operations in all our business units, including Ophthalmology, Dermatology, Neurology, Oncology, and Strategic Resourcing. Australia's expanding market aligns perfectly with our vision for growth and innovation. This expansion enables us to better integrate into the APAC region and strengthens our commitment to delivering unparalleled clinical research solutions to our global network."
While the company has previously offered geographical coverage through consultants and partner CROs in the region, this expansion represents a commitment to developing a dedicated operational base, expanding their site network and patients’ access to clical trials. Starting with Australia, TFS has plans for further growth into other countries in the APAC region, complementing existing partnerships to cater to customer needs globally.
TFS’s expansion into the APAC region enhances the company’s partnership capabilities, offering unique advantages to sponsors and partners. This strategic move not only broadens access to diverse patient populations and cutting-edge technologies but also leverages streamlined regulatory environments for faster, more efficient trial execution. By integrating this with its commitment to cultural diversity and global collaboration, TFS underlines its role as a leading CRO partner, equipped to navigate the complexities of global clinical research with precision and cultural sensitivity.
Company
TFS
Management
Young Shon, CIO
Description
Global mid-size clinical CRO focusing on small and mid-size life science customer
